维普期刊资源整合服务平台（V6.5）

29篇 您的检索式：作者名="Kupsch H"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Results of a phase Ⅰ trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer显示文摘	Richly H Kupsch P Passage K	2004	Int J Clin Pharmacol Ther2004，42，11：	1
2	Isolation of human tumor- - specific antibodies by selection Of an antibody phage library on melanoma ceils显示文摘	KUPSCH J M TIDMAN N H KANG N V et ul	1999	Clin Cancer Res1999，5，：	1
3	Reduc- tion in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease 显示文摘	KUHN A A KUPSCH A SCHNEIDER G H	2006	Eur J Neu- rosci2006，3，7：	1
4	Results of a phase I trial of sorafenib (BAY 43 9006) in combination with doxorubi cin in patients with refractory solid tumors显示文摘	Richly H Henning B F Kupsch P	2006	Ann Oncol2006，17，5：	1
5	Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxo-rubicin in patients with refractory solid tumors显示文摘	Richly H Henning BF Kupsch P	2006	Ann Oncol2006，17，：	1
6	Results of a phase Ⅰ trial of BAY 43 - 9006 in combination with doxorubicin in patients with primary hepatic cancer显示文摘	Richly H Kupsch P Passage K	2004	Int J Clin Pharmacol Ther2004，42，11：	1
7	Mutations in the connexin 26/GJB2 gene are the most common event in nonsyndromic hearing loss among the German population显示文摘	Gabriel H Kupsch P Sudendey J		0，，：	1
8	Enrichment and distribution of elements in flood-plain soils of the bitterfield industrial area-studied by neutron activation analysis 显示文摘	Schulze D Krager A Kupsch H	1997	Science of The Total Environment1997，206，2：	1
9	Results of a phase Ⅰ trial of sorafenib ( BAY 43-9006 ) in combination with doxorubicin in patients with refractory solid tumors 显示文摘	RICHLY H KUPSCH P PASSAGE K	2006	Anna Onco2006，17，5：	1
10	Mutations in the connexin26/GJB2 gene are the most commen event in non - sydromic hearing loss among the German population 显示文摘	Gabriel H Kupsch P Sudendey J	2001	Hum Mutat2001，17，：	1
11	Results of a PhaseⅠtrial of sorafenib (BAY 4329006) in combination with doxorubicin in patients with refractory solid tumors显示文摘	Richly H Henning BF Kupsch P	2006	Ann Oncol2006，17，5：	1
12	Results of a Phase Ⅰ trial of Sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors显示文摘	RICHLY H HENNING BF KUPSCH P	2006	Ann Oncol2006，17，5：	1
13	Results of a Phase I trial of sorafenib (BAY 43-9006 ) in combination with doxorubicin in patients with refractory solid tumors显示文摘	Richly H Henning BF Kupsch P	2006	Ann On- col2006，17，5：	1
14	Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer显示文摘	Richly H Kupsch P Passage K	2004	Int J Clin Pharmacol Ther2004，42，11：	1
15	Results of a phase cntrial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors显示文摘	Richly H Henning BF Kupsch P	2006	Ann Oncol2006，17，5：	1
16	Results of a Phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors 显示文摘	Richly H Henning BF Kupsch P	2006	Ann Oncol2006，17，5：	1
17	Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells 显示文摘	Kupsch J M Tidman N H Kang N V	1999	Clin Cancer Res1999，5，4：	1
18	Results ot a phase I trial of sorafenib (BAY 43 - 9006) in combination with doxorubicin in patients with refractory solid tumors 显示文摘	Richly H Henning BF Kupsch P	2006	Ann Oncol2006，17，5：	1
19	Results of a Phase Ⅰ trial of sorafenib ( BAY 43-9006 ) in combination with doxorubicin in patients with refractory solid tumors 显示文摘	RICHLY H HENNING B F KUPSCH P	2006	Ann Oncol2006，17，5：	1
20	Results of a Phase l trial of Sorafenib (BAY 43-9006) in combination with Doxorubiein in patients with refractory solid tumors 显示文摘	Richly H Henning BF Kupsch P	2006	Ann Oncol2006，17，5：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示